Polatuzumab Vedotin As a Salvage Treatment in Relapsed or Refractory DLBCL: Single Center Experience

被引：0
|
作者：
Bin Morya, Marwa [1 ]
Marei, Mohammed A. [2 ]
Tailor, Imran K. [2 ]
Alrajhi, Abdullah M. [3 ]
Alnakhli, Adel [4 ]
Alnajjar, Foud [5 ]
Alnoamani, Mohammed S. [2 ]
Alshehri, Hassan [2 ]
Motabi, Ibraheem H. [2 ]
AlShehry, Nawal [2 ]
Alfayez, Mansour [2 ]
机构：
[1] King Fahad Med City, Hematol Dept, Riyadh, Saudi Arabia
[2] King Fahad Med City, Dept Adult Hematol BMT, Comprehens Canc Ctr, Riyadh, Saudi Arabia
[3] King Fahad Med City, Hematol, Riyadth, Saudi Arabia
[4] King Fahad Med City, Clin Pharm Dept, Riyadh, Saudi Arabia
[5] King Fahad Med City, Riyadh, Saudi Arabia
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-150242
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4558
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents
    Martino, Massimo
    Festuccia, Moreno
    Fedele, Roberta
    Console, Giuseppe
    Cimminiello, Michele
    Gavarotti, Paolo
    Bruno, Benedetto
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 347 - 364
  • [32] Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL
    Chen, Robert W.
    Palmer, Joycelynne
    Siddiqi, Tanya
    Thomas, Sandra H.
    Kim, Young
    Binhong, Chen T.
    Krishnan, Amrita
    Nathwani, Nitya
    Cai, Ji-Lian
    Mott, Michelle
    Matsuoka, Deron
    Forman, Stephen J.
    BLOOD, 2012, 120 (21)
  • [33] New treatment option for relapsed or refractory DLBCL
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2019, 20 (12): : E670 - E670
  • [34] FLAG-IDA in the treatment of refractory/relapsed acute leukemia: Single center experience
    Pastore, D.
    Carluccio, F.
    Giannoccaro, M.
    Russo, Rossi A.
    Delia, M.
    Albano, F.
    Pannunzio, A.
    Casanova, M.
    Spinosa, G.
    Manduzio, P.
    Lubello, K.
    Mattia, M.
    Specchia, G.
    Liso, V
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 75 - 75
  • [35] FLAG-IDA REGIMEN AS SALVAGE THERAPY IN REFRACTORY/RELAPSED AML PATIENTS: A SINGLE-CENTER EXPERIENCE
    Delia, M.
    Pastore, D.
    Carluccio, P.
    Pasciolla, C.
    Bitetti, C.
    Franco, A.
    Anelli, L.
    Mestice, A.
    Albano, F.
    Specchia, G.
    HAEMATOLOGICA, 2016, 101 : 383 - 383
  • [36] Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison
    Wilson, Koo
    Chiodi, Francesca
    Paine, Abby
    Hakimi, Zalmai
    Ward, Victoria
    Macmillan, Tom
    Eriksson, Daniel
    Mappa, Silvia
    ADVANCES IN THERAPY, 2025, : 2445 - 2464
  • [37] Salvage treatment of relapsed/refractory LCH
    Seo, Jong Jin
    BLOOD RESEARCH, 2016, 51 (04) : 220 - 222
  • [38] Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy
    Hamadani, Mehdi
    Liao, Laura
    Wilson, Lauren
    Howarth, Amanda
    Flores, Carlos
    Chen, Lei
    BLOOD, 2022, 140 : 8058 - 8060
  • [39] SALVAGE TREATMENT WITH SINGLE-AGENT BENDAMUSTINE FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: AN ITALIAN MONOCENTRIC EXPERIENCE
    Ricciuti, G.
    Finolezzi, E.
    Falorio, S.
    Luciani, S.
    Ranucci, E.
    Angrilli, F.
    HAEMATOLOGICA, 2014, 99 : 677 - 678
  • [40] Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type
    Satoko Oka
    Kazuo Ono
    Masaharu Nohgawa
    Annals of Hematology, 2022, 101 : 2353 - 2354
12345